n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

AXON, REGN, BURL, FIVE: Jim Cramer's Views

AXON, REGN, BURL, FIVE: Jim Cramer's Views

Jim Cramer shares his views on the latest moves in biotech and retail. Account, Regeneron, Burlington Stores and Five Below are among the many stocks discussed here.

The 10 Biggest U.S. M&A Deals in 2015

The 10 Biggest U.S. M&A Deals in 2015

Health care deals dominate the list of big mergers so far this year, while tech comes in second.

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease

Data presented today at the American Society of Clinical Oncology Annual Meeting

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer likes the 10 early-stage drugs J&J has in its pipeline, among other reasons.

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

New Lifetime High For Pharmacyclics (PCYC)

New Lifetime High For Pharmacyclics (PCYC)

Trade-Ideas LLC identified Pharmacyclics (PCYC) as a new lifetime high candidate

New Ibrutinib (IMBRUVICA®) Data To Be Showcased At American Society Of Clinical Oncology (ASCO) Annual Meeting

New Ibrutinib (IMBRUVICA®) Data To Be Showcased At American Society Of Clinical Oncology (ASCO) Annual Meeting

IMBRUVICA Combination Data in Chronic Lymphocytic Leukemia to be Featured in Official ASCO Press Program

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.

Ibrutinib (IMBRUVICA®) Improves Outcomes For Pancreatic Ductal Adenocarcinoma In Mouse Models

Ibrutinib (IMBRUVICA®) Improves Outcomes For Pancreatic Ductal Adenocarcinoma In Mouse Models

- Note: This press release corresponds to abstract 396

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.

Earnings Growth Boosts AbbVie

Drug franchises are still going strong.

New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia

New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia

Data Published in The New England Journal of Medicine Show 91% Overall Response Rate and 95% Overall Survival

Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success

Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success

The drug companies' strengths in generics and knocks-off drugs should complement one another.

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan made public on Wednesday that it had made a proposal to acquire generic drugmaker Perrigo in a deal valued at $205 per share in cash and stock.

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.

Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Blogs

Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about two leadership groups that have been hammered and the spike in oil.

BioMarin Rises Amid Takeover Speculation, Price Target Raises

BioMarin Rises Amid Takeover Speculation, Price Target Raises

The shares of BioMarin are climbing after a blog reported last night that Shire is considering offering to acquire the company.

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

TheStreet Ratings team reiterated 3 stocks with a hold rating on Thursday

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.

New Ibrutinib (IMBRUVICA®) Data To Be Presented At American Association For Cancer Research (AACR) Meeting

New Ibrutinib (IMBRUVICA®) Data To Be Presented At American Association For Cancer Research (AACR) Meeting

Pre-clinical data to be presented in solid tumor and blood cancer models

Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue

Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue

It shouldn't be possible, but it never seems too late to get in.

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

It's creating investment opportunities that just shouldn't exist, Cramer says.